Valganciclovir

Product NameValganciclovir
CAS175865-60-8
MFC14H22N6O5
MW354.36
EINECS1312995-182-4
MOL File175865-60-8.mol

Chemical Properties

Density	1.59±0.1 g/cm3(Predicted)
storage temp.	Store at -20°C
solubility	Soluble in DMSO
pka	9.32±0.20(Predicted)
BCS Class	3
CAS DataBase Reference	175865-60-8(CAS DataBase Reference)

Safety Information

Hazardous Substances Data

175865-60-8(Hazardous Substances Data)

Usage And Synthesis

Uses

Antiviral.

Uses

Valganciclovir-d8, is the labeled analogue of Valganciclovir (V092000), a pro-drug of Ganciclovir, used in treatment of retro-virus.

Definition

ChEBI: The L-valinyl ester of ganciclovir, into which it is rapidly converted by intestinal and hepatic esterases. It is a synthetic analogue of 2'-deoxyguanosine.

Indications

Valganciclovir (Valcyte) is the L-valyl ester prodrug of ganciclovir.

brand name

Valcyte (Roche).

Clinical Use

Oral valganciclovir is comparable to intravenous ganciclovir for the treatment and suppression of CMV retinitis in AIDS patients.

Drug interactions

Potentially hazardous interactions with other drugs
Antibacterials: increased risk of convulsions with imipenem-cilastatin.
Antivirals: possibly increased didanosine concentration; profound myelosuppression with zidovudine - avoid if possible.
Mycophenolate: possibly increased concentrations of both mycophenolic acid and ganciclovir.
Increased risk of myelosuppression with other myelosuppressive drugs.

Metabolism

Valganciclovir is well absorbed from the gastrointestinal tract and rapidly and extensively metabolised in the intestinal wall and liver to ganciclovir. Valganciclovir is eliminated in the urine as unchanged ganciclovir, mainly by glomerular filtration and also active tubular secretion.